Instapath
Houston
About Instapath
Over 7 million Americans need biopsy procedures every year, costing over $8 billion; 20% of procedures fail to render an accurate diagnosis. Over 1 million patients have to go through costly, painful repeat biopsy procedures. Instapath makes digital microscopic imaging devices that improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing operating room capacity and hospital revenue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.2M
- Last round: Grant (Mar 2021)
- Website: instapathbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/instapath-8370 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.